On June 22, CARsgen’s “Satricabtagene Autoleucel Injection” was approved for marketing in China for the treatment of CLDN18.2-positive, HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma in patients who have failed at least two prior lines of therapy. Notably, this is the world’s first approved CAR-T therapy for solid tumors, representing a major breakthrough in the application of CAR-T in the solid tumor treatment landscape.
On June 23, CARsgen held an investor communication meeting regarding the launch of Satricabtagene Autoleucel Injection. During the meeting, CARsgen’s management disclosed that the pricing for Satricabtagene Autoleucel is set at RMB 990,000 per patient dose.
CAR-T pricing has always been a focal point of industry and patient attention. In the past, CAR-T therapies were repeatedly excluded from the basic medical insurance catalog due to their high cost. It was not until 2025, when the National Healthcare Security Administration launched the “Commercial Health Insurance Innovative Drug Catalog,” that five CAR-T therapies were successfully included in commercial insurance through negotiations. According to the previously listed prices, these five CAR-T therapies were priced between RMB 990,000 and RMB 1.29 million per dose. CARsgen’s “Satricabtagene Autoleucel Injection” is also expected to participate in this year’s medical insurance negotiations for potential inclusion in the commercial insurance catalog.
Buy Satricabtagene autoleucel from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
